LGALS9

From Wikipedia, the free encyclopedia


Lectin, galactoside-binding, soluble, 9 (galectin 9)
Identifiers
Symbol(s) LGALS9; ECALECTIN; MGC117375; MGC125973; MGC125974; galectin-9
External IDs OMIM: 601879 MGI: 109496 HomoloGene: 32078
RNA expression pattern

More reference expression data
Orthologs
Human Mouse
Entrez 3965 16859
Ensembl ENSG00000168961 ENSMUSG00000001123
Uniprot O00182 Q5SXE5
Refseq NM_002308 (mRNA)
NP_002299 (protein)		 NM_010708 (mRNA)
NP_034838 (protein)
Location Chr 17: 22.98 - 23 Mb Chr 11: 78.78 - 78.8 Mb
Pubmed search [1] [2]

Lectin, galactoside-binding, soluble, 9 (galectin 9), also known as LGALS9, is a human gene.[1]

The galectins are a family of beta-galactoside-binding proteins implicated in modulating cell-cell and cell-matrix interactions. The protein encoded by this gene is an S-type lectin. This galectin is strongly overexpressed in Hodgkin's disease tissue and it might participate in the interaction between the H&RS cells with their surrounding cells and might thus play a role in the pathogenesis of this disease and/or its consistently associated immunodeficiency. The protein has N- and C- terminal carbohydrate-binding domains connected by a link peptide. Multiple alternatively spliced transcript variants have been found for this gene.[1]

[edit] References

  1. ^ a b Entrez Gene: LGALS9 lectin, galactoside-binding, soluble, 9 (galectin 9).

[edit] Further reading

  • Hirashima M, Kashio Y, Nishi N, et al. (2004). "Galectin-9 in physiological and pathological conditions.". Glycoconj. J. 19 (7-9): 593-600. doi:10.1023/B:GLYC.0000014090.63206.2f. PMID 14758084. 
  • Maruyama K, Sugano S (1994). "Oligo-capping: a simple method to replace the cap structure of eukaryotic mRNAs with oligoribonucleotides.". Gene 138 (1-2): 171-4. PMID 8125298. 
  • Türeci O, Schmitt H, Fadle N, et al. (1997). "Molecular definition of a novel human galectin which is immunogenic in patients with Hodgkin's disease.". J. Biol. Chem. 272 (10): 6416-22. PMID 9045665. 
  • Suzuki Y, Yoshitomo-Nakagawa K, Maruyama K, et al. (1997). "Construction and characterization of a full length-enriched and a 5'-end-enriched cDNA library.". Gene 200 (1-2): 149-56. PMID 9373149. 
  • Matsumoto R, Matsumoto H, Seki M, et al. (1998). "Human ecalectin, a variant of human galectin-9, is a novel eosinophil chemoattractant produced by T lymphocytes.". J. Biol. Chem. 273 (27): 16976-84. PMID 9642261. 
  • Matsumoto R, Hirashima M, Kita H, Gleich GJ (2002). "Biological activities of ecalectin: a novel eosinophil-activating factor.". J. Immunol. 168 (4): 1961-7. PMID 11823532. 
  • Kageshita T, Kashio Y, Yamauchi A, et al. (2002). "Possible role of galectin-9 in cell aggregation and apoptosis of human melanoma cell lines and its clinical significance.". Int. J. Cancer 99 (6): 809-16. doi:10.1002/ijc.10436. PMID 12115481. 
  • Imaizumi T, Kumagai M, Sasaki N, et al. (2002). "Interferon-gamma stimulates the expression of galectin-9 in cultured human endothelial cells.". J. Leukoc. Biol. 72 (3): 486-91. PMID 12223516. 
  • Asakura H, Kashio Y, Nakamura K, et al. (2003). "Selective eosinophil adhesion to fibroblast via IFN-gamma-induced galectin-9.". J. Immunol. 169 (10): 5912-8. PMID 12421975. 
  • Strausberg RL, Feingold EA, Grouse LH, et al. (2003). "Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.". Proc. Natl. Acad. Sci. U.S.A. 99 (26): 16899-903. doi:10.1073/pnas.242603899. PMID 12477932. 
  • Kashio Y, Nakamura K, Abedin MJ, et al. (2003). "Galectin-9 induces apoptosis through the calcium-calpain-caspase-1 pathway.". J. Immunol. 170 (7): 3631-6. PMID 12646627. 
  • Abedin MJ, Kashio Y, Seki M, et al. (2003). "Potential roles of galectins in myeloid differentiation into three different lineages.". J. Leukoc. Biol. 73 (5): 650-6. PMID 12714580. 
  • Matsuda A, Suzuki Y, Honda G, et al. (2003). "Large-scale identification and characterization of human genes that activate NF-kappaB and MAPK signaling pathways.". Oncogene 22 (21): 3307-18. doi:10.1038/sj.onc.1206406. PMID 12761501. 
  • Ota T, Suzuki Y, Nishikawa T, et al. (2004). "Complete sequencing and characterization of 21,243 full-length human cDNAs.". Nat. Genet. 36 (1): 40-5. doi:10.1038/ng1285. PMID 14702039. 
  • Irie A, Yamauchi A, Kontani K, et al. (2005). "Galectin-9 as a prognostic factor with antimetastatic potential in breast cancer.". Clin. Cancer Res. 11 (8): 2962-8. doi:10.1158/1078-0432.CCR-04-0861. PMID 15837748. 
  • Kasamatsu A, Uzawa K, Nakashima D, et al. (2005). "Galectin-9 as a regulator of cellular adhesion in human oral squamous cell carcinoma cell lines.". Int. J. Mol. Med. 16 (2): 269-73. PMID 16012760. 
  • Dai SY, Nakagawa R, Itoh A, et al. (2005). "Galectin-9 induces maturation of human monocyte-derived dendritic cells.". J. Immunol. 175 (5): 2974-81. PMID 16116184. 
  • Zhu C, Anderson AC, Schubart A, et al. (2006). "The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity.". Nat. Immunol. 6 (12): 1245-52. doi:10.1038/ni1271. PMID 16286920. 
  • van de Weyer PS, Muehlfeit M, Klose C, et al. (2007). "A highly conserved tyrosine of Tim-3 is phosphorylated upon stimulation by its ligand galectin-9.". Biochem. Biophys. Res. Commun. 351 (2): 571-6. doi:10.1016/j.bbrc.2006.10.079. PMID 17069754. 
 This article on a gene on chromosome 17 is a stub. You can help Wikipedia by expanding it.